2-Cyclopentyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

Catalog No.: 
ACZVXB714
CAS No.: 
66217-55-8
Molecular Formula: 
C11H21BO2
Molecular Weight: 
196.10
2-Cyclopentyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
25g98%$135.00In stockInquiry
100g98%$418.00In stockInquiry
500g98%$1756.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-Cyclopentyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
IUPAC Name2-cyclopentyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
MDL No.MFCD31622763
Molecular FormulaC11H21BO2
Molecular Weight196.10
SMILESCC1(C)C(C)(C)OB(C2CCCC2)O1
InChI KeyBLLUYOVVBCMKHV-UHFFFAOYSA-N
Synonym2-cyclopentyl-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane;1,3,2-Dioxaborolane, 2-cyclopentyl-4,4,5,5-tetramethyl-;Cyclopentylboronic acid pinacol ester
CAS No.66217-55-8
PubChem CID13201843

Synthetic Route by SureRoute

1. ACZVXB714 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3In Stock
  4. Then
  5. ACZVXB714 route product structure diagram
    ACZVXB71466217-55-8In Stock
Inquiry

2. ACZVXB714 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACZVXB714 route product structure diagram
    ACZVXB71466217-55-8In Stock
Inquiry

3. ACZVXB714 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACZVXB714 route product structure diagram
    ACZVXB71466217-55-8In Stock
Inquiry

Comments (0)